Brief: BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development
14/06/2021 14:16
June 14 (Reuters) - Biovaxys Technology Corp BIOV.CD :
* BIOVAXYS RECEIVES POSITIVE FDA RESPONSE FOR PRE-IND REVIEW
FOR
COVIDTH CLINICAL DEVELOPMENT
Source text for Eikon: ID:nPrenpLlra
Further company coverage: BIOV.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biovaxys Technology
See all newsBrief: Biovaxys Appoints Former Sanofi Vaccines Executive To Board Of Directors
Brief: Biovaxys Announces Life Offering
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys And Horizon Technology Finance Execute Amendment To Asset Purchase Agreement
Brief: Biovaxys Announces Consolidation And Concurrent Brokered Private Placement Offering For Gross Proceeds Of Up To $3,000,000